NCT07702578 A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation Status RECRUITING Phase PHASE3
NCT07695571 Model-Informed Precision Dosing on Cyclosporine Therapy in Hematopoietic Stem Cell Transplant Recipients Status NOT_YET_RECRUITING Phase N/A
NCT07587944 Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity Status RECRUITING Phase N/A
NCT07539818 Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML Status NOT_YET_RECRUITING Phase PHASE3
NCT07516353 my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults Status NOT_YET_RECRUITING Phase NA
NCT07508982 Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML Status RECRUITING Phase PHASE1/PHASE2
NCT07493538 MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases Status RECRUITING Phase PHASE2
NCT07490288 Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML Status RECRUITING Phase NA
NCT07347171 A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies Status RECRUITING Phase PHASE1
NCT07342244 Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Status NOT_YET_RECRUITING Phase NA
NCT07131085 QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS) Status NOT_YET_RECRUITING Phase PHASE1
NCT07126782 The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT Status RECRUITING Phase EARLY_PHASE1
NCT07060612 Incidence and Risk Factors for the Development of Invasive Fungal Infection in Patients Diagnosed With Acute Myeloblastic Leukemia (HIFA) Status ACTIVE_NOT_RECRUITING Phase N/A
NCT07004816 The Mutation Profile and Prognosis in AML With IDH1/2 Mutation Status TERMINATED Phase N/A
NCT06973668 A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease Status RECRUITING Phase PHASE2